Inklusi Sosial dalam Program Kartu Jakarta Sehat (KJS) dan KARTU Jakarta Pintar (KJP) di DKI Jakarta

Article focuses on elaborating social inclusion in health and education policy in DKI Jakarta through Kartu Jakarta Sehat and Kartu Jakarta Pintar program. The program is composed by the governor and vice governor of DKI Jakarta, Joko Widodo and Basuki Tjahaja Purnama. By using interpretative method, secondary data and social exclusion and inclusion concept, this article shows that Kartu Jakarta Sehat and Kartu Jakarta Pintar program can be valued as social inclusion program. Through Kartu Jakarta Pintar program everyone who is the citizen of DKI Jakarta can participate in basic education; and through Kartu Jakarta Sehat all citizens of DKI Jakarta get merely health services. The policies make education and health services more open for all people. Participation in education and getting health services are the rights of all people. These rights were acknowledged by International community through International Convension about economic, social and cultural rights in 1966. This convention was ratified by the Indonesian Government through Law Number 11, 2005. So the normative basis of Kartu Jakarta Sehat and Kartu Jakarta Pintar Program is identified as inclusion policy in accordance with the expectation of International community and also is appropriate with the Law of Indonesia

Knowledge, attitudes and perceptions about rabies among the people in the community, healthcare professionals and veterinary practitioners in Bangladesh

It is crucial to explore knowledge, attitudes and perceptions (KAP) about rabies among the people in the community, the personnel dealing with animal bite management and suspected rabies patients, including humans and animals, to facilitate intervention in improving rabies elimination strategies. In 2016, we conducted an interactive face-to-face survey in three different districts of Bangladesh to understand the extent of KAP towards rabies in the community peoples (CPs), human healthcare professionals (HCPs) and veterinary practitioners (VPs). A set of prescribed questions was employed to measure what proportion of each group possessed sufficient knowledge, positive attitudes and adequate perceptions about rabies. A total of 1133 CPs, 211 HCPs and 168 VPs were interviewed by using a standard questionnaire comprising both closed and open-ended questions. Of the CPs, 49% identified the disease correctly (i.e. rabies is caused by an animal bite or a scratch). Only 29% of the CPs were aware that a wound should be washed immediately with soap and water after an animal bite or a scratch. However, only 49% of the CPs, 65% of the HCPs and 60% of the VPs felt that it is important to consult a physician and receive post-exposure vaccine as the first line of treatment following an animal exposure. Among the HCPs, 23% of the respondents did not possess sufficient knowledge about animal bites as categorised by the World Health Organization (WHO), and 12% of the respondents did not possess the knowledge on how to manage an animal bite properly. Out of 52% of the VPs who previously treated suspected rabid animals, only 29% had a history of taking rabies pre-exposure prophylaxis (PEP). Lack of formal education and rural subsistence were found to largely contribute to poor rabies KAP level among the CPs (P ≤ 0.01). There has been a high demand for proper training to be provided to HCPs and VPs for the effective management of an animal bite incidence in human and animals, respectively. Multi-sectoral collaboration through integrated One Health initiatives including community education, awareness programmes, facilitation of rabies PEP, and dog vaccination as well as its population control are critical in the way forward to control rabies in Bangladesh

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

BACKGROUND: Advanced recurrent ovarian cancer (ROC) is the leading cause of gynecologic cancer-related death in developed countries and new treatments are needed. Previous studies of immune checkpoint blockade showed low objective response rates (ORR) in ROC with no identified predictive biomarker. PATIENTS AND METHODS: This phase II study of pembrolizumab (NCT02674061) examined two patient cohorts with ROC: cohort A received one to three prior lines of treatment with a platinum-free interval (PFI) or treatment-free interval (TFI) between 3 and 12months and cohort B received four to six prior lines with a PFI/TFI of ≥3months. Pembrolizumab 200mg was administered intravenously every 3weeks until cancer progression, toxicity, or completion of 2years. Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS). Secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Cohort A enrolled 285 patients; the first 100 served as the training set for PD-L1 biomarker analysis. Cohort B enrolled 91 patients. ORR was 7.4% for cohort A and 9.9% for cohort B. Median DOR was 8.2months for cohort A and not reached for cohort B. DCR was 37.2% and 37.4%, respectively, in cohorts A and B. Based on the training set analysis, CPS 1 and 10 were selected for evaluation in the confirmation set. In the confirmation set, ORR was 4.1% for CPS<1, 5.7% CPS ≥1, and 10.0% for CPS ≥10. PFS was 2.1months for both cohorts. Median OS was not reached for cohort A and was 17.6months for cohort B. Toxicities were consistent with other single-agent pembrolizumab trials. CONCLUSIONS: Single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. CLINICAL TRIAL NUMBER: Clinicaltrials.gov, NCT02674061. ispartof: Ann Oncol vol:30 issue:7 pages:1080-1087 ispartof: location:England status: publishe

LBA36Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study

ispartof: Ann Oncol vol:29 Suppl 8 pages:viii728- ispartof: location:England status: publishe

Method of Analysis of the Resilience and Adaptability in Social Housing Developments through Post-occupancy Evaluation and Co-production. Final research report

The current social and climatic changes observed require an urgent revision of urbanization strategies around the world, to reduce environmental and social impacts, as well as to develop the resilience of built environments. The main challenges are the use of constructive systems and appropriate materials, design techniques and construction for specific climatic zones, besides the existent habitational adaptation with new technologies. In developing countries, the low level of quality in architecture and urbanism increase the social vulnerability that affects millions of people who find it difficult to find adequate housing, which in turn is found in precarious conditions. When the governmental housing programmes try to balance out this deficit, the low quality of defined standards lead to highly inadequate houses for the residents, obligating them to make modifications to buildings which are not necessarily prepared for these adaptations, leading to the waste of material and the inefficient use of resources. This Project will use advanced Post-Occupancy Evaluation (POE) techniques to develop methodological analysis procedures together with Social Housing Developments. The analysis will focus on the adaptive and transformative capacities alongside the resilience of the built environment in attendance to the necessities of the residents and the subsequent environmental impact caused by these ongoing transformations. The analysis will be centred on three elements: (i) BUILT ENVIRONMENT (building complex, taking into consideration the scales of the district, neighbourhood and unit, and the relation of impact between the built and natural environments; (ii) AGENTS (agents that interfere with the local social dynamic); (iii) USERS (residents of the complex). The evaluation will focus on social, functional, behavioural and environmental issues of the built environment. For verification, the methodological procedures developed will be applied to a case study in the city of Uberlandia - Brazil, specifically the undertaking of the governmental programme "minha casa, minha vida" located in the western area of the city

Childhood brain tumors: A review of strategies to translate CNS drug delivery to clinical trials

Brain tumors account for over 20% of childhood cancers and are the biggest cancer killer in children and young adults. Several initiatives over the past 40 years have tried to identify more effective drug treatments, but with very limited success. This is largely due to the bloodâ brain barrier, which restricts the entry of many drugs into the brain. In this review, we describe the main techniques that are being developed to enhance brain tumor drug delivery and explore the preclinical brain tumor models that are essential for translational development of these techniques. We also identify existing approved drugs that, if coupled with an efficient delivery method, could have potential as brain tumor treatments. Bringing this information together is part of a funded initiative to highlight drug delivery as a research strategy to overcome the current challenges for children diagnosed with brain tumors